Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
Naloxone is a fantastic tool in reducing opioid deaths, but gentler versions would be helpful for fighting overdose ...
A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...
A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...
The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...
Discover the potential of lycopene in alleviating depression. Learn how the compound found in tomatoes improves brain cell ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...
The inhaled mebufotenin candidate, dubbed GH001, was evaluated in the midstage study of 81 patients with treatment-resistant depression. The 40 patients who received GH001 saw an average 15.2 point ...
The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...
Ketamine is a short-acting anesthetic that has been used for decades in medical settings. In recent years, researchers have ...
A new study from the University of Chicago Medicine has found that people with alcohol use disorder (AUD) and depression ...
Minutes joined U.S. veterans with PTSD as they attend a week-long psychedelic retreat in Mexico. Nearly a year later, most of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback